<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00101426</url>
  </required_header>
  <id_info>
    <org_study_id>AS-3201-253</org_study_id>
    <nct_id>NCT00101426</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of AS-3201 in the Treatment of Diabetic Sensorimotor Polyneuropathy</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sumitomo Dainippon Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sumitomo Dainippon Pharma Co., Ltd.</source>
  <brief_summary>
    <textblock>
      This is a safety and efficacy trial of ranirestat(AS-3201) which is an aldose reductase
      inhibitor in patients with diabetic sensorimotor polyneuropathy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <completion_date>September 2006</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
  </secondary_outcome>
  <enrollment>500</enrollment>
  <condition>Diabetic Neuropathy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ranirestat, (AS-3201)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with the following may enter:

        Clinical signs and symptoms (footpain, numbness, tingling, weakness, etc.) of symmetrical
        distal Diabetic Sensorimotor Polyneuropathy with diagnosis by Nerve Conduction Tests and/or
        Quantitative Sensory Test.

          -  18 to 70 years old of either sex and any race

          -  Type I or Type II, insulin-dependent or non insulin-dependent diabetes for at least
             six months prior to study entry

          -  Healthy in general

          -  No hospitalizations for diabetic control or episodes of ketoacidosis for three months
             prior to screening

          -  Female patients of childbearing potential must have a negative serum pregnancy test

        Exclusion Criteria:

          -  Known non-diabetic causes of neuropathic symptoms

          -  Diabetic patients with no neuropathy or severe neuropathy

          -  Used any Aldose Reductase Inhibitors within one year of screening

          -  Clinically significant illness including unstable cardiac, pulmonary, hematologic,
             hepatic, renal, or neoplastic disease

          -  A history of systemic carcinoma within five years of screening

          -  A history of epilepsy or serious head injury

          -  A history or evidence of drug or alcohol abuse

          -  Test positive at screening for hepatitis B surface antigen or hepatitis C antibody or
             have a history of a positive result, or patients with evidence of significant hepatic
             insufficiency

          -  A history of known or suspected diagnosis of AIDS, or have tested seropositive for HIV
             antibody or antigen previously
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Toronto General Hospital, University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2005</study_first_submitted>
  <study_first_submitted_qc>January 10, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2005</study_first_posted>
  <last_update_submitted>January 10, 2008</last_update_submitted>
  <last_update_submitted_qc>January 10, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 14, 2008</last_update_posted>
  <keyword>Diabetic sensorimotor polyneuropathy</keyword>
  <keyword>Diabetic Neuropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Neuropathies</mesh_term>
    <mesh_term>Polyneuropathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

